Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity treatments continue to improve.

Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...

The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper ...

Anthony Mackie picks up the shield at a potentially awkward time. But there’s one way Disney can do right by him and the next ...

Steven Gerrard’s daughter Lilly-Ella declared she was the “luckiest” as she shared a series of Valentine’s Day love messages ...

After ending the storyline for Chris Evans' Captain America, Marvel now looks to actor Anthony Mackie to don the superhero's ...

EXCLUSIVE: Premiere Entertainment Group has licensed North American rights to Vertical for the family comedy F+, starring six ...

Universal has dropped the trailer for the highly anticipated upcoming summer blockbuster Jurassic World Rebirth, starring ...

Eli Lilly (NYSE: LLY) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in this morning's Q4 earnings report. Heading into the report, analysts ...

(Reuters) -Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing investor agitation about signs of weakness in sales of the drugs.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.